Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Dermal Cell News
Dermal Cell News is an online resource highlighting the latest research about wound healing, skin disorders, and dermal cancers.
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors
[Cancer Research] Researchers investigated the role of nitrosylation, a nitric oxide-induced post-translational modification, in melanoma progression and therapeutic resistance.
Rechallenge of Ipilimumab and Nivolumab in Advanced Melanoma Patients after Previous Ipilimumab-Based Therapy
[British Journal of Cancer] Data from advanced melanoma patients rechallenged with ipilimumab+nivolumab after previous ipilimumab-containing treatment were retrieved from the nationwide Dutch Melanoma Treatment Registry.
Stromal Lipid Species Dictate Melanoma Metastasis and Tropism
[Cancer Cell] Researchers showed that abundant stromal lipids from young subcutaneous adipocytes, including phosphatidylcholines, are taken up by melanoma cells, where they upregulate melanoma PI3K-AKT signaling, fatty acid oxidation, oxidative phosphorylation leading to oxidative stress, resulting in decreased metastatic burden.
QPS Expands Offerings With Robust Pharmacology Disease Models, Including MASH, Ulcerative Colitis, Wound Healing, and Psoriasis
[QPS (BioSpace)] QPS is pleased to announce the expansion of its pharmacology disease models portfolio to include highly relevant models for metabolic dysfunction-associated steatohepatitis (MASH), ulcerative colitis, wound healing, and psoriasis.
TREMFYA® (Guselkumab) Receives European Commission Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson’s Leadership in Inflammatory Bowel Disease
[Johnson & Johnson] Johnson & Johnson announced that the European Commission has approved a Marketing Authorisation for TREMFYA® for the treatment of adult patients with moderately to severely active ulcerative colitis who had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.
Noninvasive Transdermal Delivery of STING Agonists Reshapes the Immune Microenvironment of Melanoma and Potentiates Checkpoint Blockade Therapy Efficacy
[ACS Applied Bio Materials] Scientists developed a disulfide-bearing transdermal nanovaccine by integrating a thiol-reactive agent lipoic acid into a metal-coordinated cyclic dinucleotide nanoassembly, designated as LA-Mn-cGAMP nanovaccines.
Is Colloidal Oat an Effective Emollient Ingredient for the Prevention and Treatment of Atopic Dermatitis in Infants?
[Journal of Dermatological Treatment] The authors evaluated clinical and preclinical studies on colloidal oat-containing emollients in pediatric atopic dermatitis (AD) treatment and prevention. Studies assessing skin barrier function, immune modulation, AD prevention, food allergy risk, and healthcare utilization were included.
Aulos Bioscience Doses First Patient in Phase II Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
[AulosTM Bioscience] Aulosâ„¢ Bioscience announced dosing of its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab, and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.
A Dynamically Phase-Adaptive Regulating Hydrogel Promotes Ultrafast Anti-Fibrotic Wound Healing
[Nature Communications] A dynamically Schiff base-crosslinked hydrogel (F/R gel) with phase-adaptive regulating functions was constructed to integratedly promote rapid re-epithelialization with suppressed scars on chronic infected wounds.
Clinical Validation of Droplet Digital PCR Assays in Detecting BRAFV600-Mutant Circulating Tumor DNA As a Prognostic Biomarker in Patients with Resected Stage III Melanoma...
[The Lancet Oncology] Researchers investigated whether circulating tumour DNA measurements could predict survival outcomes during adjuvant targeted therapy or placebo treatment in stage III melanoma, thereby identifying patients at high risk and low risk of recurrence.
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Metastatic Melanoma Patients
[Cancer Immunology Research] In this Phase I trial in patients with metastatic melanoma, the cytokine GM-CSF and the innate TLR9 agonist CpG oligonucleotide were admixed with autologous tumor lysate onto a microporous poly-lactide-co-glycolide matrix polymer scaffold that achieved control over the spatial and temporal release of immunostimulatory agents in vivo.
Prolyl-tRNA Synthetase Inhibitor As a Novel First-in-Class Keloid Treatment: Downregulation of De Novo Collagen Synthesis and Inflammatory Cascade
[British Journal of Dermatology] Researchers investigated the anti-fibrotic activity of selective prolyl-tRNA synthetase inhibitors and elucidated the importance of DWN12088 as a first-in-class therapeutic agent for keloids.
As the largest organ in the human body, the skin is implicated in a wide range of health conditions. Dermal Cell News is dedicated to covering it all. Our website, newsletter, and Twitter feed highlight research on tissue regeneration in the treatment of skin wounds, burns, cancers, and disorders. We also feature relevant job postings and upcoming events.
